Amedisys Inc (NASDAQ:AMED) Insider Sells $956,881.25 in Stock

Amedisys Inc (NASDAQ:AMED) insider David L. Kemmerly sold 8,125 shares of Amedisys stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $117.77, for a total transaction of $956,881.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

David L. Kemmerly also recently made the following trade(s):

  • On Thursday, May 30th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The shares were sold at an average price of $113.48, for a total transaction of $567,400.00.
  • On Monday, May 20th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The shares were sold at an average price of $109.96, for a total transaction of $549,800.00.
  • On Friday, May 10th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The shares were sold at an average price of $115.17, for a total transaction of $575,850.00.
  • On Tuesday, May 7th, David L. Kemmerly sold 5,000 shares of Amedisys stock. The shares were sold at an average price of $118.20, for a total transaction of $591,000.00.

NASDAQ AMED traded up $0.44 during trading hours on Wednesday, reaching $118.04. 281,027 shares of the company’s stock traded hands, compared to its average volume of 452,808. Amedisys Inc has a 52-week low of $80.13 and a 52-week high of $140.91. The stock has a market cap of $3.70 billion, a P/E ratio of 32.52, a price-to-earnings-growth ratio of 1.44 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.91.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.22. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The company had revenue of $467.34 million during the quarter, compared to analysts’ expectations of $460.83 million. During the same period last year, the company posted $0.79 EPS. Amedisys’s revenue was up 17.0% on a year-over-year basis. Research analysts expect that Amedisys Inc will post 4.08 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on AMED shares. Craig Hallum cut their target price on shares of Amedisys from $132.00 to $124.00 and set a “hold” rating on the stock in a research note on Friday, March 1st. They noted that the move was a valuation call. SunTrust Banks lifted their target price on shares of Amedisys to $145.00 and gave the company a “buy” rating in a research note on Friday, March 1st. BidaskClub cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 28th. ValuEngine cut shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 27th. Finally, Raymond James raised shares of Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 price target for the company in a research report on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $129.89.

A number of hedge funds and other institutional investors have recently modified their holdings of AMED. Vanguard Group Inc raised its holdings in Amedisys by 14.3% in the third quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock worth $415,640,000 after buying an additional 415,060 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Amedisys by 15.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,900 shares of the health services provider’s stock worth $223,000 after buying an additional 251 shares during the last quarter. Xact Kapitalforvaltning AB raised its holdings in Amedisys by 14.4% in the fourth quarter. Xact Kapitalforvaltning AB now owns 5,551 shares of the health services provider’s stock worth $650,000 after buying an additional 700 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in Amedisys by 35.1% in the fourth quarter. Advisors Asset Management Inc. now owns 38,596 shares of the health services provider’s stock worth $4,520,000 after buying an additional 10,029 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Amedisys by 20.4% in the fourth quarter. Rhumbline Advisers now owns 79,058 shares of the health services provider’s stock worth $9,258,000 after buying an additional 13,414 shares during the last quarter. 86.30% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Amedisys Inc (NASDAQ:AMED) Insider Sells $956,881.25 in Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2019/06/12/amedisys-inc-nasdaqamed-insider-sells-956881-25-in-stock.html.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Read More: How does the Beige Book influence monetary policy?

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply